Capital Analysts LLC’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Analysts LLC’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-91	Closed	-$2K	–	1314
2024 Q2	$2K	Hold	91	–	–	﹤0.01%	1100
2024 Q1	$3K	Hold	91	–	–	﹤0.01%	1011
2023 Q4	$3K	Hold	91	–	–	﹤0.01%	985
2023 Q3	$3K	Sell	91 -241	-73%	-$7.88K	﹤0.01%	1007
2023 Q2	$11K	Hold	332	–	–	﹤0.01%	802
2023 Q1	$10K	Hold	332	–	–	﹤0.01%	801
2022 Q4	$9K	Sell	332 -701	-68%	-$22.2K	﹤0.01%	860
2022 Q3	$34K	Buy	1,033 +386	+60%	+$14.2K	﹤0.01%	635
2022 Q2	$20K	Buy	647 +100	+18%	+$3.5K	﹤0.01%	708
2022 Q1	$25K	Buy	547 +2	+0.4%	+$95	﹤0.01%	650
2021 Q4	$33K	Sell	545 -42	-7%	-$2.9K	﹤0.01%	631
2021 Q3	$44K	Hold	587	–	–	﹤0.01%	592
2021 Q2	$54K	Sell	587 -4,028	-87%	-$342K	﹤0.01%	548
2021 Q1	$410K	Buy	4,615 +2,428	+111%	+$241K	0.03%	269
2020 Q4	$204K	Buy	+2,187	New	+$174K	0.02%	241

Other funds holding ARKG

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Capital Analysts LLC's ARKG Position: Q3 2024 in Review

Capital Analysts LLC sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 91 shares — an estimated $2K sold.

Capital Analysts LLC first reported a position in ARKG in Q4 2020 and held it in 15 quarters. The position peaked at $410K in Q1 2021. 238 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

Capital Analysts LLC reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
Capital Analysts LLC sold 91 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $2K.
Capital Analysts LLC first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 15 quarters.
Capital Analysts LLC's ARK Genomic Revolution ETF position peaked at $410K in Q1 2021.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Capital Analysts LLC's 13F filing for Q3 2024, filed 13 Nov 2024.